GSK vs. TEVA: GSK vs. Teva Pharmaceutical Stock Comparison
How do GSK (GSK) and Teva Pharmaceutical (TEVA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
GSK (GSK) and Teva Pharmaceutical (TEVA) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.
Both GSK (GSK) and Teva Pharmaceutical (TEVA) trade as ADRs — their core financials are comparable, but keep FX, depositary-program fees, and dividend withholding in view for each.
| Profile Item | GSK | TEVA |
|---|---|---|
| Name | GSK plc ADR | Teva Pharmaceutical Industries Ltd. ADR |
| Country/Region | United Kingdom | Israel |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 100.88 billion USD | 49.72 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | March 28, 1980 | February 16, 1982 |
| Security Type | ADR | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | GSK | TEVA |
|---|---|---|
| Total Return (1Y) | 13.73% | 79.58% |
| Total Return (3Y, Annualized) | 18.65% | 69.94% |
| Total Return (5Y, Annualized) | 7.97% | 35.86% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | GSK | TEVA |
|---|---|---|
| Volatility (1Y, Annualized) | 26.25% | 33.95% |
| Beta (5Y) | 0.31 | 0.96 |
| Max Drawdown (5Y) | -37.63% | -43.70% |
| Avg. Volume (3M) | 4.05M | 5.91M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | GSK | TEVA |
|---|---|---|
| Sharpe Ratio (1Y) | 0.36 | 2.22 |
| Sortino Ratio (1Y) | 0.56 | 3.94 |
Profitability
ROE (TTM)
Both GSK (GSK) at 28.27% and Teva Pharmaceutical (TEVA) at 6.65% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.27%
- Max
- 109.18%
- GSK
- 28.27%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.65%
- Max
- 109.18%
- TEVA
- 6.65%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
GSK (GSK) at 12.97% retains a top-quartile share of revenue as profit, ahead of Teva Pharmaceutical (TEVA) at 2.94%, which keeps about the industry-typical share.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
12.97%
- Max
- 18.05%
- GSK
- 12.97%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.94%
- Max
- 18.05%
- Q3
- 4.78%
- TEVA
- 2.94%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both GSK (GSK) at 32.14% and Teva Pharmaceutical (TEVA) at 27.40% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.14%
- Max
- 83.12%
- GSK
- 32.14%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.40%
- Max
- 83.12%
- TEVA
- 27.40%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | GSK | TEVA |
|---|---|---|
| ROE (TTM) | 28.27% | 6.65% |
| ROA (TTM) | 9.24% | 5.35% |
| Net Margin (TTM) | 12.97% | 2.94% |
| Operating Margin (TTM) | 32.14% | 27.40% |
| Gross Margin (TTM) | 73.79% | 53.51% |
Growth
Revenue Growth
Both GSK (GSK) at 4.11% and Teva Pharmaceutical (TEVA) at 4.31% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: GSK (GSK) reports EPS growth of 123.15%, ranked against its industry; Teva Pharmaceutical (TEVA) has no EPS growth figure this period.
Growth Metrics
| Metric | GSK | TEVA |
|---|---|---|
| Revenue Growth (YoY) | 4.11% | 4.31% |
| Revenue Growth (3Y CAGR) | 3.66% | 4.96% |
| EPS Growth (YoY) | 123.15% | -- |
| EPS Growth (3Y CAGR) | -27.63% | -- |
Financial Strength
Current Ratio (MRQ)
Both GSK (GSK) at 0.86 and Teva Pharmaceutical (TEVA) at 0.95 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.86
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- GSK
- 0.86
- Min
- 0.10
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.95
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- TEVA
- 0.95
- Min
- 0.10
Debt / Equity (MRQ)
Both balance sheets lean debt-heavy versus peers, but TEVA is more stretched: GSK (GSK) at 1.30 sits in the higher-leverage quartile and Teva Pharmaceutical (TEVA) at 2.13 is above its industry benchmark range.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.30
- Max
- 1.42
- GSK
- 1.30
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.13
- TEVA
- 2.13
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | GSK | TEVA |
|---|---|---|
| Current Ratio (MRQ) | 0.86 | 0.95 |
| Debt / Equity (MRQ) | 1.30 | 2.13 |
| Net Debt / EBITDA | 1.88 | 2.93 |
Dividends
Dividend Yield (TTM)
Teva Pharmaceutical (TEVA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a yield of 1.57%, ranking against industry peers normally.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.57%
- GSK
- 1.57%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEVA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Teva Pharmaceutical (TEVA) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a payout of 63.33%, ranking against industry peers normally.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
63.33%
- GSK
- 63.33%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEVA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | GSK | TEVA |
|---|---|---|
| Dividend Yield (TTM) | 1.57% | 0.00% |
| Dividend Payout Ratio (TTM) | 63.33% | 0.00% |
Valuation
P/E Ratio (TTM)
GSK (GSK) at 17.54 is near its industry’s usual P/E ratio, while Teva Pharmaceutical (TEVA) at 99.09 sits above its peer range — an unusually expensive price for TEVA’s trailing earnings.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.54
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- GSK
- 17.54
- Q1
- 13.30
- Min
- 0.07
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
99.09
- TEVA
- 99.09
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Both GSK (GSK) at 3.01 and Teva Pharmaceutical (TEVA) at 2.89 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.01
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- GSK
- 3.01
- Min
- 0.01
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.89
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- TEVA
- 2.89
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both GSK (GSK) at 4.02 and Teva Pharmaceutical (TEVA) at 6.23 are valued close to their industries’ norm against book — neither stands out from peers.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.02
- Max
- 13.53
- Q3
- 6.54
- GSK
- 4.02
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.23
- Max
- 13.53
- Q3
- 6.54
- TEVA
- 6.23
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | GSK | TEVA |
|---|---|---|
| P/E Ratio (TTM) | 17.54 | 99.09 |
| P/S Ratio (TTM) | 3.01 | 2.89 |
| P/B Ratio (MRQ) | 4.02 | 6.23 |
| Free Cash Flow Yield (TTM) | 5.28% | 3.00% |